Q1 2025 Arcturus Therapeutics Holdings Inc Earnings Call Transcript
Key Points
- Arcturus Therapeutics Holdings Inc (ARCT) is advancing its mRNA therapeutics pipeline with significant progress in clinical trials for cystic fibrosis (ARCT-032) and ornithine transcarbamylase deficiency (ARCT-810).
- The company received EU approval for its self-amplifying mRNA COVID-19 vaccine, KOSTAIVE, and an initial milestone payment from its global vaccine partner, CSL.
- Arcturus Therapeutics Holdings Inc (ARCT) has extended its cash runway until the first quarter of 2028, allowing it to focus on its critical CF and OTC programs.
- The company has received US FDA fast track designation for its SA mRNA vaccine candidate for pandemic influenza A (H5N1), ARCT-2304.
- Arcturus Therapeutics Holdings Inc (ARCT) is in a strong financial position with cash and cash equivalents of $273.8 million as of March 31, 2025.
- Revenues for the first quarter of 2025 decreased to $29.4 million from $38 million in the same period of 2024, primarily due to lower development milestone revenues.
- Research and development expenses decreased to $34.9 million from $53.6 million in the comparable period last year, reflecting lower manufacturing costs but also indicating reduced activity in some areas.
- The company reported a net loss of approximately $14.1 million for the first quarter of 2025, highlighting ongoing financial challenges.
- Arcturus Therapeutics Holdings Inc (ARCT) has made the decision to focus its research and development expenditures exclusively on its CF and OTC programs, potentially limiting diversification.
- There are no anticipated milestone payments from the UK or US filings for KOSTAIVE until 2028, which may impact short-term financial expectations.
Good day. I would like to welcome everyone to Arcturus's Therapeutics first quarter 2025 earnings call. (Operator Instructions) Today's call is being recorded. I would now like to turn the call over to Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations, and Marketing. Please go ahead.
Thank you, operator. Good afternoon, and welcome to Arcturus Therapeutics quarterly financial Update and pipeline progress call. Today's call will be led by Joe Payne, our President and CEO; and Andy Sassine, our CFO. Dr. [Pad Chivukula], our CFO and COO, will join them for the Q&A session.
Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are not guarantees
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
